Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Regensburg – page 6

319 clinical trials in Regensburg, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Regensburg at a glance
319
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

319 trials in Regensburg

Open in trial search

Chronic graft versus host disease

Recruiting

Study of axatilimab compared to standard therapy in children with chronic graft-versus-host disease who have previously received at least 2 treatments

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Small cell lung cancer recurrent

Recruiting

Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited

Pulmonary arterial hypertension

Recruiting

A study of LTP001 in combination with standard treatment for adults with pulmonary arterial hypertension

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:LTP001
  • Sponsor:Novartis Pharma AG

Acute myeloid leukaemia+3

Recruiting

Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Medizinische Hochschule Hannover

Chronic graft versus host disease

Recruiting

Study of belumosudil in children aged 1 to 18 years with moderate to severe chronic graft versus host disease requiring systemic treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Belumosudil Mesilate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Diffuse large B-cell lymphoma+2

Recruiting

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Universitaet Muenster

Relapsing multiple sclerosis

Recruiting

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Novartis Pharma AG

Breast cancer+1

Recruiting

Study of typology-based coaching and education to help patients with early hormone-positive HER2-negative breast cancer manage their treatment with ribociclib

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:Institut fuer Frauengesundheit GmbH

Cholangiocarcinoma

Recruiting

Study of ivosidenib maintenance treatment in patients with IDH1-mutated cholangiocarcinoma after standard chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Colitis ulcerative

Recruiting

Study of RO7837195 injection compared to placebo to treat moderate to severe ulcerative colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:RO7837195
  • Sponsor:Genentech Inc.

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Cardiac failure

Recruiting

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Regensburg

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on breast cancer treatments, including studies of targeted therapies for HR-positive and HER2-negative variants. Research extends to lymphoma and leukemia treatments, with particular emphasis on combination therapies.

  • Breast Cancer Therapeutics
  • Blood Cancer Treatments
  • Glioma Research

Multiple studies are evaluating novel drug combinations and their impact on patient survival rates.

02 Dermatology Studies

Research focusing on preventive treatments for atopic dermatitis in high-risk pediatric populations, evaluating the effectiveness of early intervention strategies.

  • Pediatric Skin Conditions
  • Preventive Dermatology
  • Chronic Skin Disorders

Studies aim to establish new preventive protocols for childhood dermatological conditions.

03 Respiratory Medicine

Investigations into treatments for pulmonary arterial hypertension and lung fibrosis, with emphasis on novel therapeutic approaches and drug safety profiles.

  • Pulmonary Hypertension
  • Autoimmune Lung Diseases
  • Viral Lung Infections

Current trials are exploring innovative treatments for various respiratory conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.